TipRanks
Advertisement
Advertisement
Pulmatrix Pursues New Reverse Merger After Cullgen Termination
PremiumCompany AnnouncementsPulmatrix Pursues New Reverse Merger After Cullgen Termination
7M ago
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction
Premium
The Fly
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction
7M ago
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction
Premium
The Fly
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction
7M ago
Pulmatrix Reports Q3 2025 Results and Strategic Shift
PremiumCompany AnnouncementsPulmatrix Reports Q3 2025 Results and Strategic Shift
12M ago
Pulmatrix reports Q3 EPS (24c) vs. (71c) last year
Premium
The Fly
Pulmatrix reports Q3 EPS (24c) vs. (71c) last year
12M ago
Pulmatrix to potentially divest its patent portfolio for iSPERSE technology
Premium
The Fly
Pulmatrix to potentially divest its patent portfolio for iSPERSE technology
12M ago
Pulmatrix trading halted, volatility trading pause
PremiumThe FlyPulmatrix trading halted, volatility trading pause
1y ago
Pulmatrix trading resumes
Premium
The Fly
Pulmatrix trading resumes
1y ago
Pulmatrix Stockholders Approve Merger with Cullgen
Premium
Company Announcements
Pulmatrix Stockholders Approve Merger with Cullgen
1y ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―